阿斯利康(AstraZeneca)因安全问题，其潜在新冠疫苗的后期试验已被搁置

阿斯利康(AstraZeneca)是目前潜在新冠疫苗进入后期测试的三家公司之一，另外两家是辉瑞（Pfizer）和Moderna。7月，阿斯利康(AstraZeneca)公布的数据显示，其疫苗在早期试验中产生了很不错的免疫反应。据当时的研究人员称，该疫苗的耐受性良好，没有出现严重的不良反应。疲劳和头痛是报告的最多的现象，其他常见的副作用包括注射部位疼痛、肌肉酸痛、寒战和发烧。

但研究人员被告知，在英国一名参与疫苗试验的志愿者，注射疫苗后有出现疑似严重的不良反应，出于谨慎起见，阿斯利康(AstraZeneca)的后期试验被暂停。目前还不清楚试验会被搁置多久，公司表示正在努力加快审查。阿斯利康股价也因此事，在周二盘后交易中下跌超过6%。

AstraZeneca is one of three companies currently undergoing late-stage testing of a potential coronavirus vaccine, and the other two are Pfizer and Moderna. In July, AstraZeneca released data showing that its vaccine produced a very good immune response in early trials. According to researchers at the time, the vaccine was well tolerated and there were no serious adverse reactions. Fatigue and headaches are the most reported phenomena. Other common side effects include pain at the injection site, muscle aches, chills, and fever.

However, the researchers were told that a volunteer involved in a vaccine trial in the UK had a suspected serious adverse reaction after the vaccine. Out of caution, AstraZeneca's later trial was suspended. It is unclear how long the trial will be shelved, and the company said it is working to speed up the review. AstraZeneca's stock price also fell by more than 6% in after-hours trading on Tuesday.  source

指尖新闻：高信噪比，一目了然

新冠疫情追踪